Table 1.
Characteristics and taxonomic data of enrolled study participants.
| C+P+ | C+P– | C–P+ | C–P– | |
|---|---|---|---|---|
| Sex (%) | ||||
| Male | 24 (80.0%) | 17 (68.0%) | 19 (76.0%) | 11 (44.0%) |
| Female | 6 (20.0%) | 8 (32.0%) | 6 (24.0%) | 14 (56.0%) |
| Age | ||||
| Mean (SD) | 65.2 (7.4) | 65.6 (7.1) | 63.4 (7.0) | 64.8 (6.7) |
| Smoking status (%) | ||||
| Non-smokera | 13 (43.3%) | 15 (60.0%) | 17 (68.0%) | 20 (80.0%) |
| Smoker | 17 (56.7%) | 10 (40.0%) | 8 (32.0%) | 5 (20.0%) |
| Former smokerb | 4 (13.3%) | 5 (20.0%) | 1 (4.0%) | 1 (4.0%) |
| Current smokerc | 13 (43.3%) | 5 (20.0%) | 7 (28.0%) | 4 (16.0%) |
| Cigarettes/day (mean ± SD) | ||||
| Non-smoker | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Smoker | 19.4 ± 12.1 | 22 ± 7.9 | 20.5 ± 13.6 | 16.4 ± 14.4 |
| Former smoker | 13.8 ± 7.5 | 24 ± 11.4 | 20 ± N/A | 20 ± N/A |
| Current smoker | 21.8 ± 12.8 | 20 ± 0 | 20.6 ± 14.6 | 15.5 ± 16.5 |
| COPD classification (%)d | ||||
| II | 16 (53.3%) | 18 (72.0%) | / | / |
| III | 14 (46.7%) | 7 (28.0%) | / | / |
| FEV1 | ||||
| Mean (SD) | 51.9 (14.1) | 59.3 (14.3) | / | / |
| Inhaled steroids | 4 (13.3%) | 4 (16.0%) | / | / |
| OHI-S | ||||
| Mean (SD) | 2.21 (0.32) | 1.52 (0.42) | 2.18 (0.43) | 1.45 (0.51) |
| Clinical attachment loss (mm) | ||||
| Mean (SD) | 5.5 (0.7) | / | 5.9 (1.2) | / |
| Detected sequence (thousands) | ||||
| Mean (SD) | 132 (83) | 204 (63) | 178 (64) | 175 (83) |
| Classified sequence (%) | ||||
| Mean (SD) | 94.83 (0.35) | 94.61 (1.26) | 94.8 (0.59) | 94.75 (0.46) |
aNon-smokers were those who either had never smoked or quit cigarettes at least 10 years prior to study entry.
bFormer smokers were those who quit cigarettes at least 6 months but <10 years prior to study entry.
cCurrent smokers were currently smokers or those who quit cigarettes <6 months prior to study entry.
dPatients with COPD were grouped into moderate (II predicted FEV1 = 50–80%; FEV1/FVC ≤70%) and severe (III, predicted FEV1 = 30–50%; FEV1/FVC ≤70%) categories based on spirometry.